Caroline’s P.E.A.C.H. Foundation Awards Grant to Targepeutics to Advance GB13 Development for DIPG/DMG

Caroline’s P.E.A.C.H. Foundation is proud to announce a grant to Targepeutics supporting certain clinical trial expenses for GB13, an investigational therapy being developed for patients with Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG). DIPG/DMG are among the most devastating pediatric brain cancers, and the urgent need for new and effective treatment options remains. Through this grant, Caroline’s P.E.A.C.H. Foundation is reinforcing its commitment to advancing innovative research, supporting promising therapeutic approaches, and helping move scientific discoveries closer to potential clinical benefit for patients. We are honored to support Targepeutics in this important work and remain steadfast in our mission to make a difference for children and families affected by DIPG/DMG. Every step forward in research brings us closer to a future with more treatment options, more hope, and better outcomes for these children.